MGRM(Delisted)
Monogram·NASDAQ
--
--(--)
MGRM fundamentals
Monogram (MGRM) released its earnings on May 14, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.1 (YoY +9.09%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.1
+9.09%
Report date
May 14, 2025
MGRM Earnings Call Summary for Q1,2025
- Financial Strength: $13.3M cash, $1M/month burn, no debt – 12+ months of runway.
- FDA-Cleared Robot: First U.S. surgeries Q3 2025, India trial starts Q2 2025.
- Key Differentiator: Autonomous cutting reduces surgeon fatigue, costs $1.2M less per case vs. Mako.
- Growth Catalyst: 70% of new surgeons trained on robots; Monogram targets 9% market share by 2031.
- Next-Gen Hardware: Upgraded system tested in Q1, FDA-cleared robots upgradable to new version.
- Capital Plan: Seeking funding to scale post-demonstration of clinical success.
EPS
Revenue
Revenue & Expenses
Key Indicators
Monogram (MGRM) key financial stats and ratios, covering profitability, financial health, and leverage.
Monogram (MGRM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Monogram (MGRM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Monogram (MGRM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Monogram (MGRM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Monogram (MGRM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
